Not available
Quote | FibroGen Inc (NASDAQ:FGEN)
Last: | $0.691 |
---|---|
Change Percent: | -0.27% |
Open: | $0.745 |
Close: | $0.691 |
High: | $0.75 |
Low: | $0.6801 |
Volume: | 2,506,500 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | FibroGen Inc (NASDAQ:FGEN)
2024-06-28 17:32:09 ET More on FibroGen FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript FibroGen stock rall...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
Message Board Posts | FibroGen Inc (NASDAQ:FGEN)
Subject | By | Source | When |
---|---|---|---|
2.67 AH | TheFinalCD | investorshub | 06/26/2023 9:33:33 PM |
dead cat bounce? | nuclear profitz | investorshub | 06/26/2023 2:10:27 PM |
$FGEN just the news we needed | DewDiligence | investorshub | 06/24/2023 7:17:49 AM |
$FGEN Good news recently, we should start to see this one move | MikeBK205 | investorshub | 06/23/2023 11:53:12 PM |
Thoughts on where this is headed? | SealTheDeal | investorshub | 06/22/2023 1:10:34 AM |
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...